These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 31068510)

  • 1. [MYC-associated B-cell lymphomas: pathophysiology and treatment].
    Nitta H
    Rinsho Ketsueki; 2019; 60(3):155-164. PubMed ID: 31068510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
    Zayac AS; Landsburg DJ; Hughes ME; Bock AM; Nowakowski GS; Ayers EC; Girton M; Hu M; Beckman AK; Li S; Medeiros LJ; Chang JE; Stepanovic A; Kurt H; Sandoval-Sus J; Ansari-Lari MA; Kothari SK; Kress A; Xu ML; Torka P; Sundaram S; Smith SD; Naresh KN; Karimi YH; Epperla N; Bond DA; Farooq U; Saad M; Evens AM; Pandya K; Naik SG; Kamdar M; Haverkos B; Karmali R; Oh TS; Vose JM; Nutsch H; Rubinstein PG; Chaudhry A; Olszewski AJ
    Blood Adv; 2023 Nov; 7(21):6381-6394. PubMed ID: 37171397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma.
    de Jonge AV; Bult JAA; Karssing DFE; Nijland M; Chamuleau MED; Brink M
    Blood Cancer J; 2024 Jan; 14(1):2. PubMed ID: 38177113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
    Al-Juhaishi T; Wang Y; Milton DR; Xu-Monette ZY; Jabbour E; Daher M; Im JS; Bashir Q; Iyer SP; Marin D; Olson AL; Popat U; Qazilbash M; Rondon G; Gulbis AM; Champlin RE; Young KH; Khouri IF
    Bone Marrow Transplant; 2023 Sep; 58(9):1000-1007. PubMed ID: 37198234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cardiac large B cell lymphoma.
    Arun Kumar S; Mishra R; Malempati SC; Bindal P
    BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38151268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered pathways and targeted therapy in double hit lymphoma.
    Zhuang Y; Che J; Wu M; Guo Y; Xu Y; Dong X; Yang H
    J Hematol Oncol; 2022 Mar; 15(1):26. PubMed ID: 35303910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.
    Liu X; Xu S; Zhang J; Fan M; Xie J; Zhang B; Li H; Yu G; Liu Y; Zhang Y; Song J; Horne D; Chan WC; Chu X; Huang W
    Hematol Oncol; 2022 Aug; 40(3):356-369. PubMed ID: 35482553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade B-cell lymphoma with a quadruple-hit genetic profile including concurrent MYC, BCL2, BCL6, and CCND1 gene rearrangements.
    Gagnon MF; Meyer RG; Weaver EJ; Wood AJ; Dupuy DA; Menachery SJ; Shi M; Baughn LB; Ketterling RP; Peterson JF
    Lab Med; 2024 Sep; 55(5):649-654. PubMed ID: 38522075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Hwang J; Suh C; Kim K; Kim H; Kim AI; Craig JW; Chen KX; Roberson J; Guenette JP; Huang RY
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature.
    Khelfa Y; Lebowicz Y
    J Investig Med High Impact Case Rep; 2016; 4(2):2324709616642592. PubMed ID: 27115017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription.
    Frigault MM; Mithal A; Wong H; Stelte-Ludwig B; Mandava V; Huang X; Birkett J; Johnson AJ; Izumi R; Hamdy A
    Cancer Res Commun; 2023 Nov; 3(11):2268-2279. PubMed ID: 37882668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas.
    Torka P; Russell T; Mavis C; Gu J; Ghione P; Barth M; Hernandez-Ilizaliturri FJ
    Leuk Lymphoma; 2023 Jun; 64(6):1175-1185. PubMed ID: 37074033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of P53 expression on double-expressor lymphoma and characteristics of DLBCL co-expressing P53 and MYC: Clinical, pathological, and biological insights.
    Chen YZ; Bo JL; Hou SL
    Asian J Surg; 2024 Jun; 47(6):2852-2855. PubMed ID: 38408882
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Woo YR; Kwon CS; Lee JE; Jeon BE; Kim TJ; Choo J; Seo YS; Kim SW
    Curr Issues Mol Biol; 2024 May; 46(5):4580-4594. PubMed ID: 38785546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Advanced Primary Thyroid Double-Hit B Cell Lymphoma in Which Complete Remission has been Maintained After High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Performed During the Second Remission, with a Review of the Literature.
    Sekiguchi Y; Shimada A; Imai H; Wakabayashi M; Sugimoto K; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Indian J Hematol Blood Transfus; 2014 Sep; 30(Suppl 1):166-73. PubMed ID: 25332569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current challenges and novel treatment strategies in double hit lymphomas.
    Anderson MA; Tsui A; Wall M; Huang DC; Roberts AW
    Ther Adv Hematol; 2016 Feb; 7(1):52-64. PubMed ID: 26834954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study.
    Pagani C; Rusconi C; Dalla Pria A; Ravano E; Schommers P; Bastos-Oreiro M; Verga L; Gini G; Spina M; Arcaini L; Steffanoni S; Dalu D; Crucitti L; Lorenzi L; Balzarini P; Cattaneo C; Bongiovanni L; Rosenwald A; Facchetti F; Bower M; Ferreri AJM; Rossi G; Tucci A; Re A
    Blood Adv; 2024 Feb; 8(4):968-977. PubMed ID: 38207206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting MYC-driven lymphoma: lessons learned and future directions.
    Martínez-Martín S; Beaulieu ME; Soucek L
    Cancer Drug Resist; 2023; 6(2):205-222. PubMed ID: 37457123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor.
    Shi ZY; Fang Y; Xu PP; Yi HM; Li JF; Dong Y; Zhu Y; Liu MK; Fu D; Wang S; Shi Q; Shen R; Zhong HJ; Wang CF; Cheng S; Wang L; Liu F; Zhao WL
    Clin Transl Med; 2024 Jun; 14(6):e1691. PubMed ID: 38812093
    [No Abstract]   [Full Text] [Related]  

  • 20. Chidamide represses MYC expression and might improve survival for patients with double expressor lymphoma.
    Liu P; Hang X; Li J; Zhao L; Liu W; Ji J; Wu Y; Wan X; Shuai X; Guo Y; Xiang B; Liu J; Huang J; Liu Z; Hou L; Chen C; Liu Y; Liu T
    Am J Cancer Res; 2024; 14(6):2921-2933. PubMed ID: 39005667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.